Sax Wealth Advisors LLC Grows Stake in Johnson & Johnson (NYSE:JNJ)

Sax Wealth Advisors LLC increased its stake in Johnson & Johnson (NYSE:JNJ) by 17.5% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 18,938 shares of the company’s stock after buying an additional 2,814 shares during the quarter. Sax Wealth Advisors LLC’s holdings in Johnson & Johnson were worth $2,739,000 as of its most recent filing with the SEC.

Several other hedge funds have also modified their holdings of the stock. Pacer Advisors Inc. increased its position in shares of Johnson & Johnson by 15.3% during the second quarter. Pacer Advisors Inc. now owns 240,605 shares of the company’s stock worth $35,167,000 after acquiring an additional 31,908 shares during the last quarter. Sei Investments Co. increased its holdings in Johnson & Johnson by 10.7% during the 2nd quarter. Sei Investments Co. now owns 1,126,658 shares of the company’s stock worth $164,672,000 after purchasing an additional 109,205 shares during the last quarter. Thrivent Financial for Lutherans raised its position in shares of Johnson & Johnson by 31.8% in the 2nd quarter. Thrivent Financial for Lutherans now owns 1,634,863 shares of the company’s stock valued at $238,951,000 after purchasing an additional 394,518 shares in the last quarter. Kiely Wealth Advisory Group Inc. grew its position in shares of Johnson & Johnson by 5.7% during the second quarter. Kiely Wealth Advisory Group Inc. now owns 1,847 shares of the company’s stock worth $296,000 after buying an additional 99 shares in the last quarter. Finally, Summit Trail Advisors LLC increased its stake in shares of Johnson & Johnson by 30.7% in the second quarter. Summit Trail Advisors LLC now owns 45,920 shares of the company’s stock worth $6,712,000 after buying an additional 10,789 shares during the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms have commented on JNJ. Cantor Fitzgerald reiterated an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, October 16th. Guggenheim lifted their price target on Johnson & Johnson from $156.00 to $162.00 and gave the stock a “neutral” rating in a research note on Wednesday, November 6th. StockNews.com downgraded Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a report on Friday. Wolfe Research initiated coverage on Johnson & Johnson in a report on Friday, November 15th. They issued an “outperform” rating and a $190.00 price target for the company. Finally, Wells Fargo & Company raised their price objective on Johnson & Johnson from $163.00 to $166.00 and gave the stock an “equal weight” rating in a research note on Wednesday, October 16th. Seven analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $174.29.

Johnson & Johnson Trading Down 0.5 %

Shares of NYSE:JNJ opened at $147.03 on Friday. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. The company’s 50-day moving average price is $148.51 and its 200 day moving average price is $155.96. The company has a market cap of $353.99 billion, a PE ratio of 21.28, a P/E/G ratio of 2.30 and a beta of 0.51. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $168.85.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be given a dividend of $1.24 per share. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 annualized dividend and a dividend yield of 3.37%. Johnson & Johnson’s dividend payout ratio is presently 71.78%.

Insider Buying and Selling

In other Johnson & Johnson news, Director Mark A. Weinberger purchased 1,000 shares of the stock in a transaction dated Thursday, December 12th. The shares were bought at an average cost of $147.22 per share, with a total value of $147,220.00. Following the completion of the acquisition, the director now owns 1,000 shares of the company’s stock, valued at approximately $147,220. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.